Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lisinopril
Drug ID BADD_D01300
Description Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs.[A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384]
Indications and Usage Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]
Marketing Status approved; investigational
ATC Code C09AA03
DrugBank ID DB00722
KEGG ID D00362; D08131
MeSH ID D017706
PubChem ID 5362119
TTD Drug ID D07HGR
NDC Product Code 64220-154; 65862-037; 16571-797; 16571-798; 42708-031; 42708-033; 43353-270; 43353-271; 43547-417; 50090-2228; 50090-4678; 51655-707; 53002-1225; 55154-2128; 60687-325; 60760-359; 61919-246; 62135-641; 63187-099; 63629-8823; 65862-039; 65862-040; 65862-042; 68001-336; 68071-5143; 68084-196; 68645-551; 68645-587; 68645-613; 70518-0117; 70518-2600; 71335-0176; 71335-1380; 71610-612; 0615-8254; 76282-419; 76282-729; 0591-0405; 0591-0409; 0904-6797; 0904-7200; 57297-511; 63827-1012; 16729-376; 16729-379; 43353-113; 43353-993; 43547-351; 43547-355; 50090-3763; 51655-146; 55154-8096; 55289-884; 60687-333; 61919-746; 62135-642; 63187-237; 63187-442; 65862-038; 68001-334; 68071-3220; 68180-982; 68645-608; 68645-610; 68788-6407; 70518-1790; 70518-1906; 0591-0406; 71335-0354; 71610-588; 0615-8253; 72865-208; 72865-209; 76282-422; 76282-731; 76282-733; 82009-063; 65862-041; 65977-0009; 23155-714; 31722-172; 42708-142; 43353-301; 50090-3765; 50090-3774; 50090-4725; 50090-4885; 50436-0352; 50436-0354; 51655-399; 51655-729; 51655-999; 58118-1980; 60687-678; 60760-380; 62135-644; 63187-775; 63629-5247; 67296-1202; 67296-1839; 68180-517; 68180-981; 68645-550; 68645-555; 69117-0037; 70882-104; 71205-471; 71335-1295; 71610-624; 0615-8255; 61919-909; 62135-645; 63187-257; 63187-821; 63629-8736; 68001-335; 68180-513; 68645-593; 68788-7012; 68788-7334; 69117-0036; 70518-0544; 70882-103; 70934-155; 71205-180; 71205-742; 71335-0015; 71610-638; 0615-8405; 72865-210; 82009-065; 82982-066; 14593-944; 17404-0011; 16571-794; 16571-795; 42708-154; 43547-418; 43547-419; 50090-0808; 52427-441; 58118-1981; 60760-360; 61919-721; 62135-643; 63187-534; 63629-1761; 67296-1452; 68001-337; 68071-3123; 68645-552; 68645-553; 68645-609; 68788-6820; 68788-6920; 69117-0038; 69117-1003; 70518-1152; 70882-110; 70934-338; 70934-522; 70934-919; 71205-071; 76282-728; 76282-730; 82009-066; 0591-0885; 16571-796; 16729-377; 43063-480; 43063-810; 43063-812; 43547-353; 51655-486; 52427-438; 53002-1123; 60687-646; 60687-667; 63187-825; 68001-332; 68001-486; 68071-3409; 68071-5190; 68180-512; 68180-979; 68180-980; 68645-554; 68645-611; 68788-8351; 70518-0468; 70934-171; 71205-626; 0615-8252; 0904-6800; 67651-0225; 31722-179; 31722-180; 42708-176; 43063-769; 43547-352; 43547-354; 43547-356; 50090-2989; 50090-3175; 51655-995; 52652-3001; 53002-1178; 53002-1463; 60760-358; 60760-390; 60760-438; 61919-717; 61919-736; 63187-098; 63187-780; 68001-333; 68071-2224; 68071-3411; 68084-765; 70518-2561; 70518-2655; 0591-0407; 72789-093; 72789-101; 72865-211; 76282-420; 76282-421; 82009-064; 64220-142; 16729-380; 23155-710; 23155-711; 23155-712; 43063-786; 43063-800; 43063-811; 43063-813; 43353-297; 43353-643; 43353-662; 43353-793; 43547-415; 50090-6303; 51655-335; 51655-411; 52427-442; 62135-640; 63187-722; 68071-3064; 68788-8310; 69117-1001; 71335-0075; 71610-312; 71610-406; 71610-536; 72865-212; 76282-418; 0904-6798; 0904-6799; 65730-1301; 42708-096; 42708-165; 50090-2431; 50090-4887; 52427-443; 55154-4992; 55154-8078; 55700-480; 60760-357; 60760-455; 68645-532; 70518-1156; 70518-1316; 70518-3166; 0591-0408; 76282-417; 16571-799; 16729-375; 31722-176; 31722-178; 42708-032; 43063-074; 43353-009; 43353-298; 43547-414; 43547-416; 50090-5120; 50436-0353; 51655-994; 52427-440; 53002-2123; 55154-2329; 55700-479; 55700-547; 60687-656; 67296-1154; 68645-612; 68788-7666; 69117-1002; 71335-0498; 71335-0536; 72865-213; 76282-732; 82009-062; 16729-378; 23155-713; 23155-715; 31722-177; 42708-094; 43063-814; 43063-815; 52427-439
UNII E7199S1YWR
Synonyms Lisinopril | Lysinopril | Lisinopril Sulfate (1:2) | Prinivil | Zestril | Lisinopril Maleate (1:1) | MK-521
Chemical Information
Molecular Formula C21H31N3O5
CAS Registry Number 76547-98-3
SMILES C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lung neoplasm22.08.01.006; 16.19.04.001--Not Available
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010--Not Available
Non-cardiac chest pain22.12.02.009; 08.01.08.0060.000009%
Poor quality sleep19.02.05.005; 17.15.04.0020.000033%Not Available
Hepatic enzyme abnormal13.03.04.026--Not Available
Increased upper airway secretion22.12.03.0070.000005%Not Available
Cystitis noninfective20.03.02.001--
Hypophagia14.03.01.006; 07.01.06.010; 19.09.01.0040.000027%Not Available
Orthostatic intolerance02.11.01.019; 24.06.01.003; 17.05.01.0070.000005%Not Available
Lichenoid keratosis23.01.01.0040.000036%Not Available
Breath sounds abnormal13.15.01.008--Not Available
Bone marrow failure01.03.03.005--
Cytopenia01.03.03.012--Not Available
Tendon pain15.07.01.0090.000005%Not Available
Pharyngeal disorder22.04.05.0070.000012%Not Available
Adverse reaction08.06.01.0180.000015%Not Available
Focal segmental glomerulosclerosis20.05.01.0030.000011%Not Available
Upper airway obstruction22.12.03.0320.000007%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000015%Not Available
Fibrillary glomerulonephritis20.05.01.005; 10.02.01.0110.000011%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000014%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000088%
Acute kidney injury20.01.03.0160.000769%
Acute phosphate nephropathy20.05.03.006; 14.04.03.0050.000005%Not Available
Upper-airway cough syndrome22.12.03.0360.000015%
Respiratory tract oedema22.02.07.0130.000018%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000043%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000040%Not Available
Intestinal angioedema23.04.01.019; 10.01.05.019; 07.08.03.0120.000251%Not Available
The 15th Page    First    Pre   15 16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene